Showing results (161-170 of 433) with videos related to
Sort By:
Pageof 44
Journal of Medical Imaging and Radiation Oncology|June 1, 2013
Treatment response in the neck: p16+ versus p16- oropharyngeal cancerDaisy Mak, Rodney J Hicks, Danny Rischin, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 11, 2015
15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell CarcinomaKeelan Byrne, Shankar Siva, Lori Chait, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2006
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancerCuong P Duong, Rodney J Hicks, Leann Weih, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown PrimaryTharani Sivakumaran, Anthony Cardin, Jason Callahan, et al.EJNMMI Radiopharmacy and Chemistry|October 30, 2019
Automated preparation of clinical grade [68Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platformMohammad B Haskali, Peter D Roselt, David Binns, et al.Radiation Oncology (London, England)|December 17, 2014
Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumesJason Callahan, Tomas Kron, Shankar Siva, et al.Clinical Case Reports|April 12, 2018
Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and 68Ga-DOTATATE PET/CTElisa Bongetti, Melissa H Lee, David A Pattison, et al.Internal Medicine Journal|September 20, 2018
Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologistsAbby P Douglas, Karin A Thursky, Leon J Worth, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2017
Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysisSue Ping Thang, Mei Sim Lung, Grace Kong, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 12, 2014
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursRaghava Kashyap, Michael S Hofman, Michael Michael, et al.Pageof 44